TFF Pharmaceuticals, Inc. (TFFP)
| Previous close | 1.7600 |
| Open | 1.7900 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.7847 - 1.9100 |
| 52-week range | 1.5400 - 13.5000 |
| Volume | |
| Avg. volume | 38,074 |
| Market cap | 5.809M |
| Beta (5Y monthly) | 1.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -9.3800 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.00 |
GlobeNewswireTFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities
FORT WORTH, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company has engaged Outcome Capital as a strategic advisor for the purpose of evaluating potential corporate partnerships and licensing opportunities. “We are pleased to announce this en
- GlobeNewswire
TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection
FDA Provided Constructive Feedback to Help Guide Next Steps in TFF TAC Clinical Development Company to Provide More Detailed Regulatory Update in 3Q 2024 FORT WORTH, Texas, June 24, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced a regulatory update on the Company’s TFF
- GlobeNewswire
TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing
The Leidos team’s Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company’s Proprietary Thin Film Freezing Technology MCM Candidates Demonstrated Chemical and Biological (CB) Neutralizing Activity in Well-Validated In Vitro and Ex Vivo Models FORT WORTH, Texas, May 23, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on
